Compare LEGN & XP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LEGN | XP |
|---|---|---|
| Founded | 2014 | 2001 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 10.1B |
| IPO Year | 2020 | 2019 |
| Metric | LEGN | XP |
|---|---|---|
| Price | $22.34 | $17.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $69.67 | $22.40 |
| AVG Volume (30 Days) | 2.5M | ★ 8.6M |
| Earning Date | 11-12-2025 | 11-17-2025 |
| Dividend Yield | N/A | ★ 1.03% |
| EPS Growth | N/A | ★ 18.53 |
| EPS | N/A | ★ 1.76 |
| Revenue | $909,045,000.00 | ★ $3,229,174,949.00 |
| Revenue This Year | $68.83 | $17.71 |
| Revenue Next Year | $51.27 | $13.05 |
| P/E Ratio | ★ N/A | $10.07 |
| Revenue Growth | ★ 74.75 | 8.33 |
| 52 Week Low | $22.28 | $10.82 |
| 52 Week High | $45.30 | $20.64 |
| Indicator | LEGN | XP |
|---|---|---|
| Relative Strength Index (RSI) | 21.96 | 43.14 |
| Support Level | $26.43 | $17.52 |
| Resistance Level | $28.97 | $20.06 |
| Average True Range (ATR) | 1.57 | 0.71 |
| MACD | -0.43 | -0.19 |
| Stochastic Oscillator | 0.91 | 5.95 |
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.